Meropenem Antibiotice

Meropenem, the active ingredient in Meropenem Antibiotice, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It treats a broad range of serious bacterial infections in adult and pediatric patients when other antibiotics are ineffective, including intra‑abdominal infections, meningitis, pneumonia, sepsis, and complicated urinary tract infections.

GNH USA supplies Meropenem Antibiotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with European Union manufacturing standards and is distributed under strict quality controls to ensure safety and efficacy.

Meropenem is used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infection: effective against Gram‑negative and anaerobic pathogens causing peritonitis and postoperative infections. - Hospital‑acquired pneumonia: covers resistant strains of Pseudomonas and other aerobic bacteria. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate susceptible meningococci. - Complicated urinary tract infection: active against multidrug‑resistant Enterobacteriaceae. - Sepsis and febrile neutropenia: provides broad‑spectrum coverage when rapid bacterial control is needed.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: mild transaminase increase. - Injection site reaction: pain or erythema at infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity reaction. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment. - Renal toxicity: acute kidney injury in susceptible individuals. - Thrombocytopenia: marked reduction in platelet count.

Careful assessment is required before initiating meropenem therapy.

- Renal impairment: dose adjustment may be necessary to avoid accumulation. - History of seizures: monitor for neurotoxicity and consider alternative agents. - Hypersensitivity: avoid in patients with known allergy to carbapenems or β‑lactams. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: avoid because meropenem can markedly reduce valproate levels. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with several medicines, requiring clinical vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem reduces plasma concentrations, increasing seizure risk. - Live vaccines: concurrent use may diminish vaccine efficacy. - Aminoglycosides: combined nephrotoxic potential may worsen renal function.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Phenytoin: increased neurotoxicity risk; monitor neurological status. - Loop diuretics: may affect renal clearance of meropenem, adjust dosing as needed.